Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID JAX:10000006
Name Cancer of Unknown Primary
Definition Cancer for which the tissue of origin cannot be determined
Source Genomenon (a custom term added that does not correspond to an existing term in the disease ontology)
Alt Ids
Path Cancer of Unknown Primary

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MLH1 negative Pembrolizumab Cancer of Unknown Primary sensitive detail...
MSH6 negative Pembrolizumab Cancer of Unknown Primary sensitive detail...
ALK rearrange Crizotinib Cancer of Unknown Primary sensitive detail...
ALK rearrange Alectinib Cancer of Unknown Primary sensitive detail...
ALK rearrange Ceritinib Cancer of Unknown Primary sensitive detail...
ALK rearrange Brigatinib Cancer of Unknown Primary sensitive detail...
ROS1 rearrange Crizotinib Cancer of Unknown Primary sensitive detail...
FGFR2 amp Infigratinib + Trametinib Cancer of Unknown Primary sensitive detail...
FGFR2 S267P Erdafitinib Cancer of Unknown Primary predicted - sensitive detail...
BRAF V600E Binimetinib + Cetuximab Cancer of Unknown Primary predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03752333 Phase II Pembrolizumab Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem) Active, not recruiting GBR 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0